Drugs / MELANOMA-ASSOCIATED ANTIGEN 3
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00960752 Comparator | May 2010 → Jul 2020 | melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MELANOMA-ASSOCIATED ANTIGEN 3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095361 ↗ |
| Known as | MAGE-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00960752 ↗ |
| Modality | Peptide | “MAGE-3 peptide vaccine” NCT00960752 ↗ |